Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

Scienmag

MARCH 10, 2021

Using an investigational cell therapy, Medical University of South Carolina pediatricians successfully treated two patients with multisystem inflammatory syndrome in children, a rare but life-threatening complication of COVID-19.

Trials 91

Trials Clinical Trials Clinical Trials Allergies 91

Scienmag

OCTOBER 21, 2020

Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.

Drugs 73

Drugs Research Clinical Trials Clinical Trials 73

Scienmag

DECEMBER 1, 2020

December 2, 2020) – Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use of high-dose Octagam® 10% [Immune Globulin Intravenous (Human)] […].

Clinical Research 46

Clinical Research Research Clinical Trials Clinical Trials 46

Scienmag

DECEMBER 2, 2020

December 3, 2020) – Octapharma USA will present multiple clinical research posters focused on the efficacy and safety of fibryga®, Fibrinogen (Human) Lyophilized Powder for Reconstitution, for Intravenous Use in the treatment of congenital and acquired bleeding disorders during the 62nd American […].

Research 40

Research Clinical Research Clinical Trials Clinical Trials 40

The Pharma Data

NOVEMBER 4, 2020

Progressed European regulatory review and commercial preparations : Continued to support regulatory review of VASCEPA by the European Medicines Agency (EMA) with the expectation of an early 2021 approval of VASCEPA for commercial sale in Europe. Patients with such allergies should discontinue VASCEPA if any reactions occur.

Sales 40

Sales Production Cardiology Marketing 40

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98